Join our daily newsletter At The Bell to receive exclusive market insights
- Dimerix (DXB) has announced the last patient in its phase two clinical study has received their final dose of DMX-200.
- The study is evaluating the safety and efficacy of DMX-200 on patients with diabetic kidney disease
- DMX-200 is a chemokine receptor blocker given to patients that are taking the standard of care treatment for kidney disease
- Dimerix believes DMX-200 has the potential to significantly reduce the costly and time-consuming burden the global disease has on patients and the healthcare system
- Results from the study are expected in four to six weeks
- Dimerix shares are trading flat at 38 cents in early afternoon trade
Dimerix (DXB) has announced the last patient in its phase two clinical study has received their final dose of DMX-200.
All critical data has been collected and the Data Safety Monitoring Board hasn’t flagged any safety concerns.
The phase two study is a double-blind, randomised, placebo-controlled study that is designed to evaluate the safety and efficacy of DMX-200 on patients with diabetic kidney disease who are receiving a steady dose of an angiotensin receptor blocker called irbesartan.
DMX-200 is a chemokine receptor blocker and is administered to patients taking irbesartan. Irbesartan is an angiotensin II type I receptor blocker and the standard of care treatment for kidney disease.
Each participant received DMX-200 for 12 weeks and a placebo for 12 weeks. However the two period were separated by a minimum six-week ‘washout’ period.
The main endpoint for the study is the percentage change from baseline in 24-hour albumin (protein made by liver) to creatinine (breakdown product responsible for filtering out waste from body) ratio after 12 weeks of being treated with DMX-200 as opposed to placebos in patients who are receiving irbesartan.
The secondary endpoints include efficacy measures such as the frequency of patients achieving an albumin reduction of 30 per cent ore more. Other measures include key kidney functions, as well as the safety profile of DMX-200 compared to placebo.
Dimerix has proudly provided continued access to DMX-200 for a number of patients who have completed the study.
In 2017, there were 23 million diagnosed diabetics in the U.S and 40 per cent of all diabetics suffer from kidney disease which there is no cure for as of yet. The incidence of diabetes is expected to grow by 54 per cent by 2040.
Dimerix hopes DMX-200 can significantly increase the life of kidney and reduce the costs and time-consuming clinical visits for patients and the healthcare system.
The company expects the top-line results will be provided within four to six weeks.
Dimerix shares are trading flat at 38 cents each in early afternoon trade.
